Avanos Medical (AVNS) director awarded 12,003 cash-settled restricted share units
Avanos Medical director Patrick J. O’Leary was granted 12,003 cash-settled restricted share units on May 8, 2026, as compensation. These units, which replace an earlier grant from January 2, 2025, represent a contingent right to a cash payment equivalent to the value of one share of Avanos common stock and will vest upon the termination of O’Leary's service on the company's Board of Directors. This compensation structure aims to align his incentives with the company's long-term performance and board service.
Avanos Medical (NYSE: AVNS) director awarded 12,003 cash-settled RSUs
Avanos Medical director Indrani Lall Franchini was granted 12,003 cash-settled Restricted Share Units (RSUs) on May 8, 2026, replacing a prior grant from January 2, 2025. These RSUs represent a contingent right to receive a cash payment equal to the value of one share of Avanos common stock and will vest upon the termination of her service on the company's Board of Directors. The grant aims to align her incentives with her continued board tenure.
Avanos Medical (AVNS) director awarded 12,003 cash-settled RSUs
Avanos Medical director Gary Blackford was granted 12,003 cash-settled Restricted Share Units (RSUs) on May 8, 2026. These RSUs replace an earlier grant from January 2, 2025 and will vest upon his termination of service from the company's Board of Directors. Each RSU represents a contingent right to a cash payment equal to the value of one share of Avanos common stock, aligning his incentives with the company's performance.
Avanos Medical (NYSE: AVNS) director awarded 12,003 cash-settled restricted units
Avanos Medical (AVNS) director Lisa Egbuonu-Davis was granted 12,003 cash-settled restricted share units on May 8, 2026. These units replace a previous grant and will vest upon her termination of service from the company's Board of Directors. The Form 4 filing indicates a compensation-related grant, not an open-market transaction of shares.
A Look At Avanos Medical (AVNS) Valuation After Sharp Recent Share Price Gains
Avanos Medical (AVNS) has seen a significant surge in its share price recently, with an 80.94% increase in one month and 121.56% year-to-date, despite a 36.03% loss over five years. The company, currently valued at US$1.16 billion with US$715.9 million in revenue and a US$74.4 million net loss, trades at a Price-to-Sales (P/S) ratio of 1.6x. While this is lower than industry averages, it appears slightly richer than its estimated fair P/S of 1.2x, suggesting potential for valuation adjustment if market sentiment shifts.
(AVNS) Movement as an Input in Quant Signal Sets
This article analyzes Avanos Medical Inc. (NASDAQ: AVNS) using AI models, identifying neutral near and mid-term readings that could moderate a long-term positive bias. It provides specific institutional trading strategies, including long, momentum breakout, and risk hedging, along with multi-timeframe signal analysis indicating support and resistance levels. The report highlights elevated downside risk due to a lack of additional long-term support signals.
A Look At Avanos Medical (AVNS) Valuation After Sharp Recent Share Price Gains
Avanos Medical (AVNS) has seen significant recent share price gains of 80.94% in one month and 121.56% year-to-date, despite a 36.03% loss over five years. The company, valued at US$1.16 billion with US$715.9 million in revenue and a US$74.4 million net loss, trades at a Price-to-Sales (P/S) ratio of 1.6x. While this is below industry averages, it's considered "about right" but richer than its estimated fair P/S of 1.2x, suggesting potential for valuation adjustment if sentiment shifts.
Avanos Medical stock hits 52-week high at 24.76 USD
Avanos Medical Inc. (AVNS) stock reached a 52-week high of $24.76 USD, reflecting a 96.82% 1-year change and nearly 120% year-to-date returns. The company is set to be acquired by American Industrial Partners for approximately $1.272 billion, with stockholders receiving $25.00 per share. InvestingPro analysis indicates the stock is undervalued relative to its Fair Value and has a "GOOD" financial health score.
Avanos Medical stock hits 52-week high at 24.76 USD By Investing.com
Avanos Medical (AVNS) stock reached a 52-week high of $24.76, demonstrating a strong performance with a 96.82% 1-year change and nearly 120% year-to-date returns. The company's market capitalization stands at $1.16 billion, trading significantly above its 52-week low. This surge is attributed to strategic initiatives, operational efficiencies, and a broader rally in the healthcare sector, with InvestingPro analysis suggesting the stock remains undervalued relative to its Fair Value.
Avanos Medical (AVNS) Trailing EPS Loss Of US$1.57 Challenges Bullish Community Narratives
Avanos Medical (AVNS) reported a trailing twelve-month basic EPS loss of US$1.57 and a net loss of US$72.9 million on US$701.2 million in revenue, leading to challenges against bullish narratives. The company's profitability has weakened over the past five years, with losses increasing despite quarterly revenues generally staying between US$167.5 million and US$180.9 million. While the stock trades at a lower P/S ratio compared to the industry and has a 17% discount to its DCF fair value, significant questions remain regarding earnings quality and operational stability due to inconsistent profits.
[10-Q] AVANOS MEDICAL, INC. Quarterly Earnings Report
Avanos Medical, Inc. (AVNS) released its first-quarter 2026 earnings report, showing a rise in net sales to $182.2 million from $167.5 million, primarily driven by its Specialty Nutrition Systems segment. Despite the revenue growth, net income decreased to $5.1 million from $6.6 million. The report also highlights a pending cash merger where affiliates of American Industrial Partners will acquire Avanos for $25.00 per share, which, upon completion, will result in the company's delisting from the NYSE.
Avanos Medical earnings ahead as private equity deal looms
Avanos Medical Inc. is set to report its first-quarter earnings, potentially one of its last as a public company, amid a pending $1.3 billion acquisition by American Industrial Partners. Analysts forecast earnings of $0.24 per share on $169 million in revenue, a sequential dip but a year-over-year improvement. Investors will be watching for updates on full-year guidance, sequential performance, and the acquisition timeline given the deal is expected to close in the second half of 2026.
Avanos Medical (AVNS) posts Q1 2026 results and $1.272B AIP buyout deal
Avanos Medical (AVNS) reported its Q1 2026 financial results, including net sales of $182.2 million, an increase of 8.8% year-over-year, largely driven by its Specialty Nutrition Systems segment. Despite revenue growth, net income decreased to $5.1 million from $6.6 million in the prior year, and the company experienced a significant shift from positive to negative free cash flow. The report also highlighted the pending all-cash acquisition of Avanos Medical by affiliates of American Industrial Partners for an enterprise value of $1.272 billion.
Avanos Medical (AVNS) Trailing EPS Loss Of US$1.57 Challenges Bullish Community Narratives
Avanos Medical (AVNS) reported a Q1 2026 basic EPS loss of US$1.57 and a net loss of US$72.9 million for the trailing twelve months, despite revenues ranging from US$167.5 million to US$180.9 million per quarter. The company's profitability has worsened over five years, with critics noting persistent losses and volatile earnings. Despite trading at a P/S of 1.6x—below industry averages and its DCF fair value—the continued losses and high share price volatility concern investors.
Earnings Flash (AVNS) Avanos Medical, Inc. Reports Q1 Revenue $182.2M, vs. FactSet Est of $170.0M
Avanos Medical, Inc. (AVNS) reported its Q1 revenue reached $182.2 million, surpassing the FactSet estimated $170.0 million. This financial update indicates a stronger performance than anticipated by analysts for the quarter ended March 31, 2026. The company is a medical technology company specializing in medical device solutions.
Press Releases about Avanos Medical, Inc. Common Stock (NYSE:AVNS)
This article compiles recent press releases concerning Avanos Medical, Inc. (NYSE:AVNS), focusing on several law firms investigating the company. These investigations center on whether AVNS is obtaining a fair deal for its shareholders in proposed transactions, specifically mentioning a potential sale to American Industrial Partners for $25.00 per share. Law firms like Halper Sadeh LLC, Brodsky & Smith LLC, Ademi LLP, and Kahn Swick & Foti, LLC are urging shareholders to contact them to discuss these investigations.
Avanos Medical stock hits 52-week high at 24.72 USD
Avanos Medical (AVNS) stock reached a new 52-week high of $24.72, reflecting a 97% surge over the past year and a 120% year-to-date return, with the stock climbing nearly 166% from its 52-week low. This surge is attributed to investor confidence and positive company developments, including a recent acquisition by American Industrial Partners for approximately $1.27 billion, offering stockholders $25.00 per share. The company also increased its CEO's long-term incentive target and plans to nominate two new independent directors, while analysts maintain a "Market Perform" rating.
Avanos Medical (NYSE: AVNS) SVP has shares withheld to cover RSU taxes
Avanos Medical's SVP of Operations, Sigfrido Delgado, had 4,264 shares withheld at a price of $24.64 per share to cover tax obligations upon the vesting of 16,300 time-based restricted share units (TRSUs). This transaction, valued at $105,000, was a non-market disposition for tax withholding purposes. Following this, Delgado directly holds 55,741 shares of Avanos Medical common stock.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Helix Energy Solutions Group, Inc. (NYSE – HLX), TopBuild Corp. (NYSE – BLD), Avanos Medical, Inc. (NYSE – AVNS), Affinity Bancshares (Nasdaq – AFBI)
Brodsky & Smith LLC is notifying investors about ongoing investigations into the acquisitions of Helix Energy Solutions Group, TopBuild Corp., Avanos Medical, Inc., and Affinity Bancshares. The investigations concern whether the respective company boards breached their fiduciary duties by failing to conduct fair processes and ensuring fair value for shareholders in these proposed transactions. Shareholders are encouraged to contact Brodsky & Smith to discuss the investigations without cost or financial obligation.
Shareholder Alert: Ademi LLP investigates whether Avanos
Ademi LLP is investigating Avanos Medical Inc. (NYSE: AVNS) for potential breaches of fiduciary duty regarding its transaction with American Industrial, valued at approximately $1.272 billion where shareholders will receive $25.00 per share. The firm is examining whether the board of directors is fulfilling its duties, particularly concerning the significant penalty imposed for competing bids and the benefits Avanos insiders stand to receive. Shareholders are invited to join the investigation to determine if they are receiving a fair price.
Avanos Medical rockets 67% on $1.27B acquisition by American Industrial Partners
Avanos Medical surged 67% following its acquisition by American Industrial Partners for approximately $1.27 billion. Shareholders will receive $21 per share in cash, representing a substantial premium over the stock's previous closing price. The deal is expected to close in Q3 2026, pending regulatory and shareholder approvals.
Avanos Medical Inc stock (US05350V1061): Why Google Discover changes matter more now
Google's 2026 Discover Core Update significantly alters how investors access information on stocks like Avanos Medical Inc (NYSE: AVNS) by prioritizing personalized, mobile-first delivery of financial news directly to the Google app feed. This shift means faster access to critical updates—such as product launches or regulatory changes—without needing to search, offering a potential edge in the fast-paced healthcare sector. For investors, enabling Web & App Activity and following AVNS-related queries will enhance personalization, allowing for timely insights on market dynamics and strategic developments.
Avanos Medical (NYSE:AVNS) Lowered to "Hold" Rating by Wall Street Zen
Wall Street Zen downgraded Avanos Medical (NYSE:AVNS) from "buy" to "hold," contributing to a consensus "Reduce" rating on MarketBeat. Despite beating Q4 earnings and revenue estimates, the company's FY2026 EPS guidance fell below sell-side expectations, impacting analyst sentiment. Institutional ownership remains very high at 95.17%, with significant increases in positions from major funds like Northwestern Mutual Wealth Management Co.
Avanos (NYSE: AVNS) CEO surrenders 21,194 shares to cover RSU taxes
Avanos Medical, Inc. CEO David Pacitti surrendered 21,194 shares of Common Stock to the company to cover tax withholding obligations. This transaction occurred upon the vesting of 72,614 time-based restricted share units (RSUs), with each share valued at $14.53 for tax purposes. Following this non-open market disposition, Pacitti directly holds 322,194 shares of Common Stock.
Top 2 Health Care Stocks That May Fall Off A Cliff In Q2
This article identifies two healthcare stocks, Avanos Medical (AVNS) and Revolution Medicines (RVMD), that are currently considered overbought based on their Relative Strength Index (RSI) values. Avanos Medical recently agreed to an acquisition, causing its stock to surge, while Revolution Medicines priced significant share and convertible note offerings. Both companies have experienced substantial gains over the past five days, leading to high RSI values indicating potential for a short-term pullback.
Avanos Medical to begin a new chapter: Acquired by AIP in $1.27bn deal
Avanos Medical is set to be acquired by affiliates of American Industrial Partners (AIP) in an all-cash deal valued at $1.272 billion. Stockholders will receive $25 per share, a 72.1% premium over the closing price on April 13, 2026. This acquisition will take Avanos private, granting it enhanced flexibility and resources for long-term growth and innovation.
Avanos Medical Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avanos Medical, Inc. - AVNS
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Avanos Medical, Inc. (NYSE: AVNS) to affiliates of American Industrial Partners for an offer of $25.00 cash per share. KSF aims to determine if this consideration and the sale process are adequate or if the Company is undervalued. Shareholders are encouraged to contact KSF if they believe the transaction undervalues the company or wish to discuss their legal rights.
AIP to acquire Avanos Medical in $1.27B go-private deal
American Industrial Partners (AIP) is set to acquire Avanos Medical in a $1.27 billion go-private deal, offering a 72.1% premium to its Monday closing stock price. Avanos, which generated $701.2 million in net sales last year, competes in specialty nutrition and pain management markets against major players. The acquisition is expected to provide Avanos with enhanced flexibility and resources to strengthen its competitive position and advance its innovation roadmap, aiming for $1 billion in revenue by 2030.
Why Is Avanos Medical Stock Skyrocketing Tuesday? - Avanos Medical (NYSE:AVNS)
Avanos Medical (NYSE: AVNS) stock is skyrocketing after American Industrial Partners announced an all-cash buyout, taking the company private in a $1.27 billion deal. Shareholders will receive $25.00 per share, representing a 72.1% premium. The acquisition, unanimously approved by Avanos' board, is expected to close in the second half of 2026 and follows a recent earnings beat.
AIP to acquire Avanos Medical in $1.27B go-private deal
American Industrial Partners (AIP) has agreed to acquire Avanos Medical in a $1.27 billion go-private deal. The acquisition, which offers a 72.1% premium to Avanos's recent closing stock price, aims to strengthen Avanos's competitive position in the specialty nutrition and pain management markets. Avanos CEO Dave Pacitti stated that AIP's backing will support the company's innovation roadmap and goal of reaching $1 billion in revenue by 2030, following recent portfolio adjustments and restructuring efforts.
Avanos Medical Inc (AVNS) Stock Up 69.5% but GF Value Says Overvalued
Avanos Medical Inc (AVNS) shares surged 69.5%, reaching $24.63, significantly outperforming recent market trends. Despite this impressive gain, GuruFocus's GF Value™ suggests the stock is 23.9% overvalued at $19.88, indicating a potential lack of margin of safety for new investors. The company holds a GF Score™ of 73/100, highlighting strong financial health but weaker growth prospects, and there have been no insider transactions recently.
Avanos Medical stock surges on $1.27B buyout by AIP
Avanos Medical Inc. (NYSE:AVNS) shares surged almost 70% after the company announced its definitive agreement to be acquired by affiliates of American Industrial Partners (AIP) for an all-cash consideration of $25.00 per share. This represents a significant premium to Avanos's recent closing stock prices, valuing the company at approximately $1.272 billion. The transaction, approved by Avanos's Board, is expected to close in the second half of 2026, after which Avanos will become a private entity.
Avanos Medical Stock Is Rising 69%. Here’s Why.
Avanos Medical stock experienced a significant 69% rise due to a buyout offer. The acquiring company is purchasing Avanos Medical for nearly double its market value, leading to a substantial premium for shareholders. This event marks a reversal for Avanos Medical's stock, which had been in decline since 2018.
Avanos Medical, Inc. Agrees To Be Acquired by American Industrial Partners for Approximately $1.272 Billion
Avanos Medical, Inc. (NYSE: AVNS) has announced a definitive agreement to be acquired by American Industrial Partners (AIP), a private equity firm, for approximately $1.272 billion. Under the terms of the agreement, Avanos shareholders will receive $21.75 per share in cash, representing a 20.3% premium over its closing stock price on April 12, 2026. The transaction, unanimously approved by Avanos' board, is expected to close in the second half of 2026, subject to shareholder and regulatory approvals.
Avanos Medical agrees to be acquired by private equity firm in $1.3B deal
Avanos Medical has announced an agreement to be acquired by American Industrial Partners (AIP) for approximately $1.272 billion in an all-cash transaction. Stockholders will receive $25 per share, representing a 72.1% premium to the previous day's closing price. This deal highlights a continuing trend of private equity investment in the medical technology sector.
Avanos (AVNS) Stock Surges 67% on $1.27 Billion Acquisition Deal
Avanos Medical Inc (AVNS) announced its acquisition by American Industrial Partners for $1.27 billion, causing its stock price to surge over 67% in pre-market trading. The all-cash deal offers shareholders $25 per share, representing a significant premium. While Avanos exhibits financial strength, its low growth rank suggests potential long-term challenges, despite the lucrative acquisition terms for investors.
AIP to take Avanos Medical private in $1.27 billion deal
American Industrial Partners (AIP) has agreed to acquire Avanos Medical in an all-cash deal valued at approximately $1.27 billion. The acquisition focuses on Avanos Medical's nutrition and pain management offerings, including its flagship Coolief device which uses radiofrequency technology for chronic pain relief without opioids. Avanos shareholders will receive $25 per share, representing a 72.1% premium to its last close, with the deal expected to finalize in the second half of 2026.
Avanos Medical rockets 67% on $1.27B acquisition by American Industrial Partners
Avanos Medical is being acquired by American Industrial Partners for $1.27 billion, causing its stock to surge 67%. The medical technology company will become private, with shareholders receiving $21.00 per share in cash. This acquisition aims to enhance Avanos's focus on its core medical technology business.
Avanos Medical, Inc. Agrees To Be Acquired by American Industrial Partners for Approximately $1.272 Billion
Avanos Medical, Inc. has entered a definitive agreement to be acquired by American Industrial Partners (AIP) for approximately $1.272 billion. Avanos stockholders will receive $25.00 per share in cash, representing a significant premium over recent trading prices. The transaction, unanimously approved by Avanos' Board, is expected to close in the second half of 2026, after which Avanos will become a private company.
AIP to take Avanos (NYSE: AVNS) private at $25 per share
Avanos Medical, Inc. (NYSE: AVNS) has agreed to be acquired by affiliates of American Industrial Partners (AIP) in an all-cash deal valued at approximately $1.272 billion. Avanos stockholders will receive $25.00 per share, representing a significant premium over recent trading prices. The transaction, unanimously approved by Avanos's Board, is expected to close in the second half of 2026, after which Avanos will become a private company and its shares will be delisted from the NYSE.
AVNS SEC Filings - Avanos Medical 10-K, 10-Q, 8-K Forms
This page provides access to Avanos Medical (AVNS) SEC filings including 10-K, 10-Q, and 8-K reports, offering investors insights into financial performance, strategic actions, and governance. Stock Titan enhances these filings with AI-powered summaries, impact scoring, and sentiment analysis for quick understanding of key points. Recent filings cover 2025 financial results, insider stock sales, ownership updates from investment firms, and executive severance details.
Book value per share of Avanos Medical, Inc. – FWB:8HH
This article focuses on the book value per share of Avanos Medical, Inc., traded on the Frankfurt Stock Exchange under the ticker FWB:8HH. It presents a financial metric within the context of the company's market and financial data. The content primarily highlights this specific financial detail without elaborating further.
EBIT per share of Avanos Medical, Inc. – FWB:8HH
The article presents the EBIT per share for Avanos Medical, Inc. (FWB:8HH). It includes the period, value, change, and percentage change without providing specific figures in the snippet. The information is sourced from TradingView, with market and reference data from ICE Data Services and FactSet, respectively.
Understanding Momentum Shifts in (AVNS)
This article analyzes momentum shifts for Avanos Medical Inc. (NASDAQ: AVNS), identifying a neutral sentiment across all time horizons and suggesting a wait-and-see approach. It details distinct AI-generated trading strategies for various risk profiles, including position, momentum breakout, and risk-hedging strategies. The analysis highlights an exceptional risk-reward short setup and provides multi-timeframe signal analysis with support and resistance levels.
AVANOS MEDICAL prepares for ASRA annual meeting with live ultrasound demo on April 17, 2026
AVANOS MEDICAL announced its participation in the American Society of Regional Anesthesia and Pain Medicine Annual Meeting in April 2026. The company will host a live ultrasound screening demonstration at booth 314 on April 17, 2026, to showcase its ONQ and Ambit product lines. This participation highlights AVANOS MEDICAL's continued commitment to advancements in pain medicine, following their recent release of the RxCrush Pill Crushing System.
AVNS Technical Analysis & Stock Price Forecast
The article provides a technical analysis for Avanos Medical Inc (AVNS), indicating a "Strong Buy" consensus based on various indicators as of April 2, 2026. Key metrics such as MACD, moving averages, and momentum indicators suggest positive short-term momentum, while RSI shows a neutral condition. The stock is trading above its 60-day and 200-day moving averages, with identified support and resistance levels.
AVNS SEC Filings - Avanos Medical 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Avanos Medical (AVNS) SEC filings, including 10-K, 10-Q, and 8-K forms, with AI-powered summaries and sentiment analysis. It details how Avanos uses these filings to report financial performance, strategic actions, and governance matters. The platform also offers real-time access to EDGAR data and AI-generated overviews to help investors quickly understand key information.
AVNS Should I Buy
Intellectia.AI advises against buying Avanos Medical Inc (AVNS) for beginner investors with a long-term strategy, recommending a "Hold" position instead. The analysis is based on mixed technical indicators, weak financial performance in Q4 2025 (including significant drops in net income and EPS), and a lack of strong positive catalysts. While Barclays raised its price target slightly, it's not enough to warrant a strong buy signal, and stock trend analysis predicts a potential decline in the near future.
Avanos (NYSE: AVNS) CEO Pacitti receives new option and RSU grants
Avanos Medical CEO David Pacitti received new equity awards on March 13, 2026, including options to purchase 239,354 shares and 101,341 time-based restricted share units. These awards, which vest over three years, are intended to align his compensation with the company's long-term performance. This transaction increases his direct common stock holdings to 343,388 shares and is considered a routine equity grant rather than a trading signal.
CFO at Avanos (NYSE: AVNS) awarded new stock options and RSUs
Avanos Medical's SVP and CFO, Scott Michael Galovan, has received new equity awards, including 69,630 employee stock options at an exercise price of $13.69 and 29,481 shares of Common Stock. These awards, granted under the company's 2021 Long Term Incentive Plan, increase his total holdings to 96,212 options and 139,824 direct shares. The common stock awards are time-based restricted share units (TRSUs) that will vest in scheduled installments on March 13, 2027, 2028, and 2029, aligning a portion of his compensation with the company’s long-term performance.
